Trial Profile
A Randomized, Double-blind, Placebo-controlled Parallel Arm Dose Titration Study to Assess the Effects of SAR407899 in Patients With Microvascular Angina (MVA) and/or Persistent Stable Angina Despite Angiographically Successful Percutaneous Coronary Intervention (PCI)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs SAR 407899 (Primary) ; Adenosine; Regadenoson
- Indications Angina pectoris; Coronary artery disease
- Focus Therapeutic Use
- Sponsors Sanofi
- 03 Aug 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 17 Aug 2018 Status changed from recruiting to discontinued due to slow recruitment. Not linked to any safety concern.
- 03 Oct 2017 Status changed from not yet recruiting to recruiting.